Skip to main content

Enstilar FDA Approval History

FDA Approved: Yes (First approved October 16, 2015)
Brand name: Enstilar
Generic name: betamethasone dipropionate and calcipotriene
Dosage form: Foam
Company: LEO Pharma Inc.
Treatment for: Plaque Psoriasis

Enstilar (betamethasone dipropionate and calcipotriene) is a topical corticosteroid and vitamin D analogue foam formulation for the treatment of psoriasis vulgaris.

Development timeline for Enstilar

Oct 19, 2015Approval LEO Pharma Announces U.S. Approval of Enstilar Foam (calcipotriene/betamethasone dipropionate) for Plaque Psoriasis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.